Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

NICE’s fast-track catapults Skyrizi into market

NICE’s fast-track catapults Skyrizi into market

All told, that means Skyrizi (risankizumab), an IL-23 inhibitor, has gained market access in England in less than five months after its European marketing approval on 30 April. ... Skyrizi is not the end of AbbVie's ambitions in the field – it also has

Latest news

  • AbbVie scores FDA approval for arthritis treatment upadacitinib AbbVie scores FDA approval for arthritis treatment upadacitinib

    arthritis. . The oral JAK inhibitor met all primary and secondary endpoints across its phase 3 SELECT programme, which supported the FDA’s decision to approve the drug. ... The JAK inhibitor market competition has also become increasingly saturated

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Inrebic (fedratinib) is the second JAK inhibitor to be approved for myelofibrosis since Incyte’s Jakafi (ruxolitinib) was cleared by the FDA in 2011, and the first new treatment for the ... JAK1/2 inhibitor Jakafi is currently the only FDA-approved

  • AbbVie’s Skyrizi gets rapid ‘yes’ from NICE AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

    Skyrizi is a new entrant to the IL-23 inhibitor class, but has an advantage in being administered only every 12 weeks, compared to once every four weeks for established treatments. ... Skyrizi is not the end of AbbVie's ambitions in the field - it also

  • GSK pushes rheumatoid arthritis antibody into phase 3 GSK pushes rheumatoid arthritis antibody into phase 3

    antibody Kevzara (sarilumab) and Pfizer’s JAK inhibitor Xeljanz (tofacitinib), to try to differentiate its drug. ... such as new JAK inhibitor from AbbVie ( upadacitinib) and Gilead ( filgotinib).

  • AbbVie’s upadacitinib tops Humira again in arthritis trial AbbVie’s upadacitinib tops Humira again in arthritis trial

    Firm says pipeline drug only JAK inhibitor to show superiority. AbbVie‘s JAK inhibitor upadacitinib works better than its blockbuster Humira in keeping rheumatoid arthritis (RA) patients in clinical remission over ... Upadacitinib is “the only JAK

More from news
Approximately 4 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch January 2018

    Acquisition company -  remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera. ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302,

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during September 2013 Pharma deals during September 2013

    cancer, and AT13387, a second generation HSP90 inhibitor for the treatment of prostate and lung cancers. ... antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

  • Pharma deals during October 2012 Pharma deals during October 2012

    Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... 60. ‡‡Ethical Oncology Science / Servier.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics